Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis
Johann Sellner, Paulus Rommer
Autoimmunity Reviews (2019) Vol. 18, Iss. 3, pp. 255-261
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

The role of TH17 cells in multiple sclerosis: Therapeutic implications
Tobias Moser, Katja Akgün, Undine Proschmann, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 10, pp. 102647-102647
Closed Access | Times Cited: 212
Digital Twins for Multiple Sclerosis
Isabel Voigt, Hernán Inojosa, Anja Dillenseger, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 193
Clinical outcome measures in multiple sclerosis: A review
Hernán Inojosa, Dirk Schriefer, Tjalf Ziemssen
Autoimmunity Reviews (2020) Vol. 19, Iss. 5, pp. 102512-102512
Closed Access | Times Cited: 138
Immunological Aspects of Approved MS Therapeutics
Paulus Rommer, Ron Milo, May Han, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 137
Use of natalizumab in persons with multiple sclerosis: 2022 update
Sarah A. Morrow, Fraser Clift, Virginia Devonshire, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 65, pp. 103995-103995
Open Access | Times Cited: 37
Advances of Regulatory B Cells in Autoimmune Diseases
Qiugang Zhu, Ke Rui, Shengjun Wang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 36
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
Aurora Zanghì, Antonio Gallo, Carlo Avolio, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 2, pp. 1166-1174
Open Access | Times Cited: 33
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials
Fan Tang, Yan Tie, Yuquan Wei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188606-188606
Open Access | Times Cited: 32
Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario
Lorena Lorefice, Paolo Mellino, Jessica Frau, et al.
Neurological Sciences (2024) Vol. 45, Iss. 8, pp. 3951-3959
Closed Access | Times Cited: 4
Multiple Sklerose
Friedemann Paul, Roland Seifert
Springer eBooks (2025), pp. 537-558
Closed Access
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis
Lucia Moiola, Paulus Rommer, Uwe K. Zettl
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 286-294
Closed Access | Times Cited: 31
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
Tobias Moser, Tjalf Ziemssen, Johann Sellner
Wiener Medizinische Wochenschrift (2022) Vol. 172, Iss. 15-16, pp. 365-372
Open Access | Times Cited: 16
Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod
Yára Dadalti Fragoso, Tarso Adoni, Sidney Gomes, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 9, pp. 909-913
Closed Access | Times Cited: 26
Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy
Xuerui Zhang, Lulu Song, Lin Li, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 22
Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
Cristina Scarpazza, Nicola De Rossi, Giulietta Tabiadon, et al.
Neurological Sciences (2019) Vol. 40, Iss. 10, pp. 2119-2124
Closed Access | Times Cited: 24
Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
Kyle Smoot, Chiayi Chen, Tamela Stuchiner, et al.
BMJ Neurology Open (2021) Vol. 3, Iss. 2, pp. e000108-e000108
Open Access | Times Cited: 19
Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials
Zhao Zhao, Chun-Lai Ma, Zhi‐Chun Gu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 18
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)
Kévin Bigaut, Mikaël Cohen, Françoise Durand‐Dubief, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 53, pp. 103076-103076
Open Access | Times Cited: 18
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?
Oliver Findling, Johann Sellner
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 416-428
Closed Access | Times Cited: 17
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia
Mohammed Aljumah, Ahmad Abulaban, Hani Aggad, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 51, pp. 102925-102925
Open Access | Times Cited: 15
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
Elisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 1, pp. 93-101
Closed Access | Times Cited: 15
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry
Niklas Frahm, Firas Fneish, David Ellenberger, et al.
Neurology and Therapy (2022) Vol. 11, Iss. 1, pp. 319-336
Open Access | Times Cited: 9
Mechanisms of antigen-induced reversal of CNS inflammation in experimental demyelinating disease
Jian Li, Lisen Lu, Kyle Binder, et al.
Science Advances (2023) Vol. 9, Iss. 9
Open Access | Times Cited: 5
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
Monica Margoni, Francesca Rinaldi, Silvia Miante, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2019) Vol. 5, Iss. 3
Open Access | Times Cited: 15
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice
Carrie M. Hersh, Haleigh Harris, Devon Conway, et al.
Neurology Clinical Practice (2020) Vol. 10, Iss. 6
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top